2020
Alcohol-Associated Liver Disease
Liu M, Sehrawat T, Szabo G, Shah V. Alcohol-Associated Liver Disease. 2020, 309-324. DOI: 10.1007/978-3-030-51709-0_20.Peer-Reviewed Original ResearchThe knowns and unknowns of treatment for alcoholic hepatitis
Sehrawat T, Liu M, Shah V. The knowns and unknowns of treatment for alcoholic hepatitis. The Lancet Gastroenterology & Hepatology 2020, 5: 494-506. PMID: 32277902, PMCID: PMC7238289, DOI: 10.1016/s2468-1253(19)30326-7.Peer-Reviewed Original ResearchConceptsAlcoholic hepatitisLiver diseaseSevere alcoholic hepatitisInflammatory liver diseaseChronic liver diseaseOngoing clinical trialsEffective medical treatmentMedical therapyHigh morbidityClinical trialsHepatitisPreclinical studiesNew therapiesRapid onsetMedical treatmentMyriad complicationsEffective therapeuticsModest effectivenessAlcohol dependencySeries paperPatientsTherapyDiseaseTreatmentLong term
2016
Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics
Chang K, Liu M. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Current Opinion In Pharmacology 2016, 30: 93-105. PMID: 27570126, DOI: 10.1016/j.coph.2016.07.013.Peer-Reviewed Original ResearchConceptsImmune modulatory approachesChronic hepatitis B.Chronic viral infectionsHost immune componentsImmune pathogenesisHBV infectionFunctional cureHepatitis BHepatitis B.Tumor immunotherapyModulatory approachesImmune componentsImmune interactionsClinical developmentViral infectionDisease pathogenesisNatural historyPathogenic responsesAspects of hostImmunotherapeuticsPathogenesisTumor therapyInfectionImmunotherapyTherapy